Merus N.V.

15.35+0.1300+0.85%Vol 192.78K1Y Perf -41.48%
Nov 30th, 2022 16:00 DELAYED
BID13.50 ASK17.07
Open15.47 Previous Close15.22
Pre-Market- After-Market16.11
 - -  0.76 4.95%
Target Price
41.50 
Analyst Rating
Strong Buy 1.10
Potential %
170.36 
Finscreener Ranking
★★★★     54.34
Insiders Trans % 3/6/12 mo.
-/-33/-50 
Value Ranking
★★+     49.42
Insiders Value % 3/6/12 mo.
81/-88/-89 
Growth Ranking
★★★     52.16
Insiders Shares Cnt. % 3/6/12 mo.
77/-87/-87 
Income Ranking
 —    -
Price Range Ratio 52W %
15.76 
Earnings Rating
Strong Sell
Market Cap710.74M 
Earnings Date
1st Nov 2022
Alpha0.01 Standard Deviation0.18
Beta0.91 

Today's Price Range

15.1015.84

52W Range

12.0333.09

5 Year PE Ratio Range

-8.50-6.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.16%
1 Month
-25.12%
3 Months
-37.53%
6 Months
-18.26%
1 Year
-41.48%
3 Years
-6.86%
5 Years
-6.69%
10 Years
-

TickerPriceChg.Chg.%
MRUS15.350.13000.85
AAPL148.036.86004.86
GOOG101.456.01006.30
MSFT255.1414.81006.16
XOM111.340.80000.72
WFC47.950.38000.80
JNJ178.001.91001.08
FB196.640.99000.51
GE85.970.31000.36
JPM138.181.62001.19
 
ProfitabilityValueIndustryS&P 500US Markets
-
-283.20
-280.40
-244.20
-99.95
RevenueValueIndustryS&P 500US Markets
45.63M
0.99
14.31
45.50
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.60-0.5311.67
Q02 2022-0.65-0.1380.00
Q01 2022-0.66-0.4334.85
Q04 2021-0.58-0.3441.38
Q03 2021-0.66-0.3940.91
Q02 2021-0.60-0.71-18.33
Q01 2021-0.22-0.28-27.27
Q04 2020-0.61-0.77-26.23
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.85-37.10Negative
12/2022 FY-1.97-9.44Negative
3/2023 QR-0.88-383.87Negative
12/2023 FY-3.32-53.00Negative
Next Report Date-
Estimated EPS Next Report-0.60
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume192.78K
Shares Outstanding46.30K
Shares Float43.37M
Trades Count3.21K
Dollar Volume2.96M
Avg. Volume318.92K
Avg. Weekly Volume172.77K
Avg. Monthly Volume451.44K
Avg. Quarterly Volume332.54K

Merus N.V. (NASDAQ: MRUS) stock closed at 15.35 per share at the end of the most recent trading day (a 0.85% change compared to the prior day closing price) with a volume of 192.78K shares and market capitalization of 710.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 132 people. Merus N.V. CEO is Sven Ante Lundberg.

The one-year performance of Merus N.V. stock is -41.48%, while year-to-date (YTD) performance is -51.73%. MRUS stock has a five-year performance of -6.69%. Its 52-week range is between 12.03 and 33.09, which gives MRUS stock a 52-week price range ratio of 15.76%

Merus N.V. currently has a PE ratio of -10.60, a price-to-book (PB) ratio of 2.36, a price-to-sale (PS) ratio of 15.44, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.51%, a ROC of -24.39% and a ROE of -25.23%. The company’s profit margin is -99.95%, its EBITDA margin is -280.40%, and its revenue ttm is $45.63 Million , which makes it $0.99 revenue per share.

Of the last four earnings reports from Merus N.V., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Merus N.V.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Merus N.V. is Strong Buy (1.1), with a target price of $41.5, which is +170.36% compared to the current price. The earnings rating for Merus N.V. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Merus N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Merus N.V. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.59, ATR14 : 1.42, CCI20 : -84.53, Chaikin Money Flow : 0.19, MACD : -1.34, Money Flow Index : 27.99, ROC : -17.25, RSI : 34.80, STOCH (14,3) : 15.57, STOCH RSI : 0.32, UO : 37.26, Williams %R : -84.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Merus N.V. in the last 12-months were: Harry Shuman (Option Excercise at a value of $0), Harry Shuman (Sold 740 shares of value $14 543 ), Peter B. Silverman (Option Excercise at a value of $669 600), Peter B. Silverman (Sold 60 000 shares of value $1 617 000 ), Sven Ante Lundberg (Buy at a value of $249 430)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (90.00 %)
9 (81.82 %)
9 (81.82 %)
Moderate Buy
1 (10.00 %)
1 (9.09 %)
1 (9.09 %)
Hold
0 (0.00 %)
1 (9.09 %)
1 (9.09 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.27
Strong Buy
1.27

Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

CEO: Sven Ante Lundberg

Telephone: +31 302538800

Address: Yalelaan 62, Utrecht 3584 CM, , NL

Number of employees: 132

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

48%52%

Bearish Bullish

55%45%

TipRanks News for MRUS

Wed, 21 Sep 2022 03:50 GMT Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), Merus (MRUS) and Genfit SA (GNFT)

- TipRanks. All rights reserved.

Thu, 11 Aug 2022 03:15 GMT Merus (MRUS) Gets a Buy from SVB Securities

- TipRanks. All rights reserved.

News

Stocktwits